Author

L. Luberto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:human· 1 Assay:protein sequence· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

E. Marra· 3 shared A. M. Anastasi· 2 shared A. Riccio· 2 shared A. Rosi· 2 shared A. Rossi· 2 shared C. Chiapparino· 2 shared C. Viollet· 2 shared D. Santapaola· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

E. Marra

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery

F. M. Milazzo, A. Chaves-Sanjuan, O. Minenkova, D. Santapaola, A. M. Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, E. Merlo Pich, C. Albertoni, E. Marra, L. Luberto, C. Viollet, L. G. Spagnoli, A. Riccio, , R. De Santis

The paper shows that scFv76 antibody neutralizes multiple SARS-CoV-2 variants and reduces lung damage in mice when delivered via aerosol.

bioRxiv · May 27, 2022Microbiology

COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

A. Conforti, E. Marra, F. Palombo, G. Roscilli, M. Rava, V. Fumagalli, A. Muzi, M. Maffei, L. Luberto, L. Lione, E. Salvatori, M. Compagnone, E. Pinto, E. Pavoni, F. Bucci, , De F

This paper evaluates a DNA vaccine candidate, COVID-eVax, which induces strong neutralizing antibodies and T cell responses against SARS-CoV-2 in animal models, showing protective effects against viral challenge.

bioRxiv · Jun 14, 2021 · PreprintImmunology

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy

O. Minenkova, D. Santapaola, F. M. Milazzo, A. M. Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, G. Gritti, G. Borleri, A. Rambaldi, C. Dental, C. Viollet, B. Pagano, L. Salvini, E. Marra, , R. De Santis

This study identifies human antibody fragments that neutralize SARS-CoV-2 variants and show efficacy in animal models, suggesting potential for early COVID-19 therapy.

bioRxiv · Jun 4, 2021Bioengineering